Published in
American Society of Hematology, Blood, 8(125), p. 1282-1291, 2015
DOI: 10.1182/blood-2014-04-570960
Links
- American Society of Hematology | PDF
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia
Journal article published in 2015 by
Dagmar Schinnerl,
Klaus Fortschegger,
Maximilian Kauer,
João R. M. Marchante,
Reinhard Kofler,
Monique L. Den Boer,
Sabine Strehl 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points PAX5-JAK2 is the first nuclear DNA-binding JAK2 fusion protein with kinase activity. JAK2 inhibitors block the kinase activity of PAX5-JAK2.